全胰切除术后双激素人工胰腺闭环控糖与现行糖尿病管理的随机对照试验
该随机交叉试验纳入12例全胰切除术后成人门诊患者,比较全闭环双激素人工胰腺(BIHAP)与现行糖尿病管理(胰岛素泵或笔注射)的血糖控制效果。主要结局为连续血糖监测的血糖正常时间比例,BIHAP组显著高于现行管理组,低血糖时间显著更低,无严重不良事件。
要点
- 全胰切除术后患者使用BIHAP可显著提高血糖正常时间比例(中位78.30% vs 57.38%)。
- BIHAP组低血糖时间显著低于现行管理组(中位0.00% vs 1.61%)。
- BIHAP使用期间未发生严重不良事件,安全性良好。
核心结论
- 全胰切除术后患者使用BIHAP较现行糖尿病管理可增加血糖正常时间比例并减少低血糖时间,且无明显安全风险。
研究设计与样本
- 随机交叉临床试验,纳入12例全胰切除术后成人门诊患者,先进行2例可行性阶段,随后12例随机分配至7天BIHAP(前有5天训练期)后7天现行糖尿病管理,或相反顺序。
主要发现
- 未发生严重不良事件。
临床怎么用
- 对于全胰切除术后血糖控制困难的患者,BIHAP可能是一种改善血糖控制并减少低血糖的安全选择。
局限性
- 样本量小(12例),治疗时间短(各7天),且3例未完成BIHAP阶段,1例被替换;需更大规模、更长周期的随机试验确认并评估生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glucose control in patients after total pancreatectomy is problematic because of the complete absence of α- and β-cells, leading to impaired quality of life. A novel, bihormonal artificial pancreas (BIHAP), using both insulin and glucagon, may improve glucose control, but studies in this setting are lacking. OBJECTIVE: To assess the efficacy and safety of the BIHAP in patients after total pancreatectomy. DESIGN, SETTING, AND PARTICIPANTS: This randomized crossover clinical trial compared the fully closed-loop BIHAP with current diabetes care (ie, insulin pump or pen therapy) in 12 adult outpatients after total pancreatectomy. Patients were recruited between August 21 and November 16, 2020. This first-in-patient study began with a feasibility phase in 2 patients. Subsequently, 12 patients were randomly assigned to 7-day treatment with the BIHAP (preceded by a 5-day training period) followed by 7-day treatment with current diabetes care, or the same treatments in reverse order. Statistical analysis was by Wilcoxon signed rank and Mann-Whitney U tests, with significance set at a 2-sided P < .05. MAIN OUTCOMES AND MEASURES: The primary outcome was the percentage of time spent in euglycemia (70-180 mg/dL [3.9-10 mmol/L]) as assessed by continuous glucose monitoring. RESULTS: In total, 12 patients (7 men and 3 women; median [IQR] age, 62.5 [43.1-74.0] years) were randomly assigned, of whom 3 did not complete the BIHAP phase and 1 was replaced. The time spent in euglycemia was significantly higher during treatment with the BIHAP (median, 78.30%; IQR, 71.05%-82.61%) than current diabetes care (median, 57.38%; IQR, 52.38%-81.35%; P = .03). In addition, the time spent in hypoglycemia (<70 mg/dL [3.9 mmol/L]) was lower with the BIHAP (median, 0.00% [IQR, 0.00%-0.07%] vs 1.61% [IQR, 0.80%-3.81%]; P = .004). No serious adverse events occurred. CONCLUSIONS AND RELEVANCE: Patients using the BIHAP after total pancreatectomy experienced an increased percentage of time in euglycemia and a reduced percentage of time in hypoglycemia compared with current diabetes care, without apparent safety risks. Larger randomized trials, including longer periods of treatment and an assessment of quality of life, should confirm these findings. TRIAL REGISTRATION: trialregister.nl Identifier: NL8871.
引用
- van Veldhuisen CL, Latenstein AEJ, Blauw H, et al. Bihormonal Artificial Pancreas With Closed-Loop Glucose Control vs Current Diabetes Care After Total Pancreatectomy: A Randomized Clinical Trial. JAMA Surg. 2022. PMID: 36069928. doi:10.1001/jamasurg.2022.3702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。